The mission of the Pharmacology Core is to provide analytical and pharmacokinetic support for Research Projects in this application. Pharmacology Core staff will provide advice on design of pharmacokinetic studies and sampling protocols, coordinate the collection and proper storage of all blood samples for the Program, perform measurements of serum or plasma concentrations of drugs and metabolites, and provide pharmacokinetic analyses for the laboratory projects. By establishing a central facility for planning and coordination of blood sampling protocols and the analysis of drug and/or metabolite concentrations in blood and other biological samples, this Core will minimize duplication f efforts and maximize success in obtaining the analytical and pharmacokinetic precision and information needed to accomplish the proposed research. High performance liquid chromatographic and gas chromatographic-mass spectrometric assays are available to measure plasma concentrations of drugs and metabolites for Projects 11 and 8. Core staff have developed assays for busulfan and for pentoxifylline and its active metabolites (M1 and M5), for the proposed research projects. Additionally, this Core will assist Project 8 with separation and purification of PTX analog enantiomers and will include a research component addressing several aspects of BU pharmacokinetics as they relate to improving methods of BU administration in transplant patients. As a centralized facility, the Pharmacology Core will assure dependable, high quality analytical support for the pharmacokinetic aspects of the supported research projects in an economical manner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA047748-06
Application #
3751048
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Bensinger, W I (2009) Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 23:442-8
Bensinger, William (2008) Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 26:480-92
Bensinger, William I (2007) Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Best Pract Res Clin Haematol 20:783-95
Bensinger, William I (2007) Reduced intensity allogeneic stem cell transplantation in multiple myeloma. Front Biosci 12:4384-92
Zaucha, Renata E; Buckner, Dean C; Barnett, Todd et al. (2006) Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. Int J Radiat Oncol Biol Phys 64:227-34
Bensinger, W I (2006) The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 20:1683-9
Bensinger, William I (2004) The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma. J Natl Compr Canc Netw 2:371-8
Bensinger, William I (2004) The current status of hematopoietic stem cell transplantation for multiple myeloma. Clin Adv Hematol Oncol 2:46-52
Yusuf, U; Frangoul, H A; Gooley, T A et al. (2004) Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 33:805-14
Einsele, H; Bamberg, M; Budach, W et al. (2003) A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplant 32:593-9

Showing the most recent 10 out of 150 publications